Patent ID: 11952588
Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method of treating a human subject having a hematologic malignancy, comprising:
(a) administering to the human subject:
one or more graft versus host disease (GVHD) prophylactic agents;
a population of cells comprising a dose of 5×105 to 2×107 donor hematopoietic stem and progenitor cells (HSPCs) per kilogram of body weight of the human subject, wherein the HSPCs comprise less than 2% CD3+ cells;
a population of cells comprising a dose of 1×106 to 5×106 donor regulatory T cells (Tregs) per kilogram of body weight of the human subject, wherein at least 80% of the nucleated cells administered in the population of cells comprising a dose of donor Tregs are FOXP3+ cells; and
a population of cells comprising a dose of 1×106 to 5×106 donor CD3+ conventional T cells (Tcons) per kilogram of body weight of the human subject, and

(b) myeloablative conditioning of the human subject prior to the administration of the population of cells comprising a dose of HSPCs, the population of cells comprising a dose of Tregs, and/or the population of cells comprising a dose of Tcons.